Categories Uncategorized

Why Psychedelic Dosage Matters

Finding the right dosage is a major challenge, not just with psychedelics, but any other drug. Some people try microdosing and fail to get any results. Others overdose and get bad trips. It really is a question of trial and error, but a wrong dose is the cause of many psychedelic-related problems.

Considering people are different, the effects of the dose will not be the same from one person to another. It doesn’t matter whether you are microdosing or taking very high doses, the effect and how well the drug functions varies. That’s why finding the correct psychedelic dosage matters.

Even if a substance is labelled as being a good remedy, it becomes poisonous to the body if taken incorrectly. This is to say dosage is a key factor in altering a drug’s effects. Take this as an example, imagine a person taking a shot of vodka while another takes a whole bottle of vodka. The impact will be different and they will have different experiences even though they both took vodka. The difference is in quantity. This same mechanism applies in psychedelic dosing.

Non-toxic substances, such as LSD and psilocybin, can still have negative effects on a patient’s wellbeing. If taken in abundance, it can cause ‘poisonous’ experiences.

Though set and setting are situations that may result in a bad trip, dosage is the key factor. Most studies show that taking psychedelic treatments in a noisy place, and surrounded by people can result in bad trips. What if an individual was in a different safe and quiet environment but instead took a high dosage? Will they not have a bad trip?

A Boston psychonaut, the late Kilindi Iyi, supported this notion when he stated that set and setting doesn’t matter whatsoever in situations where a patient takes high doses of magic mushrooms. This means that dosage is a vital factor in psychedelic sessions.

Before taking matters in your own hands and exploring substances, read below some practical tips.

  • Use scales
    Instead of using your naked eyes to judge how much of a substance you should take, consider getting a scale to carefully weigh the amount
  • Get the right doses for both intranasal and oral doses
    The dosage may be different depending on the route of administration, so keep that in mind while deciding how much to consume
  • Increase the dose gradually
    Don’t bombard your body with a high dose as this can have unwanted effects. Start small, then increase gradually
  • Utilize boosters
    After the first dose, add a second one to boost its effect as the substance slowly builds up in your system
  • Keep a drug journal
    Get personalized data by keeping track and logging your ingestions while taking notes of the effects

Understandably, not everyone is designed to be meticulous and adhere to all the suggestions above, and that could explain why psychedelics companies like Eleusis Ltd. insist that these substances should only be administered in a clinical setting where professionals can supervise the entire process.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

2 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

4 months ago